BEECH: A dose-finding run-in followed by a randomised phase 2 study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with oestrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population

Published 2019 View Full Article

Authors

Keywords

Journal

ANNALS OF ONCOLOGY

Volume -, Issue -, Pages -

Publisher

Oxford University Press (OUP)

Online

2019-03-11

DOI

10.1093/annonc/mdz086

Ask authors/readers for more resources

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

ANNALS OF ONCOLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Discover Peeref hubs

Ask a Question. Answer a Question.